World's largest maker of store-brand over-the-counter health and infant-formula products for retailers.
World's largest maker of store-brand over-the-counter health and infant-formula products for retailers.
Splits between store-brand products it makes for retailers' own labels in the US, where it competes on price and supply reliability, and its own branded consumer-health lines in Europe, built through the 2015 Omega Pharma purchase. It sold its generic prescription-drug business in 2021 and later added Opill, a non-prescription contraceptive pill, through its HRA Pharma purchase.
Moat: narrow (scale, cost advantage, regulatory licence). Scale manufacturing and FDA-registered facilities are costly barriers for smaller store-brand suppliers.
Headquarters: Dublin, Ireland · Founded: 1887 · Employees: 8,100
Size Perrigo (PRGO) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $2.35B, the 1679th largest of 3,085 United States companies the cockpit tracks. Shares closed at $16.94 on 18 Nov 2026.
Performance Over six months the shares gained 51.8%, against -11.5% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue fell 4.5% over the last twelve months (peer median +4.2%); the operating margin is 4.6% (peer median 11.1%).
Valuation It trades at 6.7× forward earnings against a peer median of 26.2× (cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +13 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.1 points below its cost of capital (6.8% WACC).
Credit Perrigo has 3 bonds outstanding ($1.77B), rated B+ by the agencies and trading like BB at a weighted spread of 184 bp.
Short interest Short interest is 17.7% of the free float (30 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $4.09B | $4.25B | $4.37B | $4.66B | $4.45B |
| Revenue growth | — | -3% | -6% | +5% | — |
| Gross profit | $1.32B | $1.50B | $1.54B | $1.68B | $1.46B |
| EBITDA | $617M | $682M | $644M | $642M | $512M |
| Net income | -$1.77B | -$1.43B | -$172M | -$12.7M | -$141M |
| Free cash flow | $168M | $145M | $245M | $304M | $211M |
| Capital expenditure | $72.4M | $94.9M | $132M | $102M | $96.4M |
| Total debt | $3.45B | $3.82B | $3.80B | $4.26B | $4.32B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Perrigo PRGO | $2.35B | +52% | -4% | 5% | 6.7× | 14.1% |
| Kenvue KVUE | n/a | +12% | n/a | n/a | n/a | n/a |
| Reckitt Benckiser RKT.L | $47.5B | +22% | -2% | 28% | 16.7× | 2.1% |
| Church & Dwight CHD | $26.4B | +16% | +2% | 18% | 28.1× | 7.7% |
| Haleon HLN.L | $39.6B | 0% | +1% | 23% | 16.4× | 5.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PRGO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.8% | -5.5% | 2nd highest of 21 |
| 6-month return | +51.8% | -11.5% | 2nd highest of 21 |
| Distance from 52-week high | -0.8% | -33.1% | highest of 21 |
| Revenue growth (TTM) | -4.5% | +4.2% | 9th lowest of 20 |
| Operating margin | 4.6% | 11.1% | 7th lowest of 19 |
| Forward P/E | 6.7× | 26.2× | cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 14.1% | 3.3% | 6th most demanding of 15 |
| Growth delivered (Del g) | +0.8% | +11.1% | 4th lowest of 15 |
| Hurdle (Req g minus delivered) | +13.3 pp | -0.5 pp | 5th most demanding of 15 |
| ROIC minus cost of capital | -4.1 pp | -1.3 pp | 5th lowest of 15 |
| EV / EBITDA | 8.7× | 13.7× | cheapest of 6 |
| Net debt / EBITDA | 4.9× | -0.6× | 2nd most indebted of 7 |
| Bond spread | 184 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Perrigo PRGO | United States | $2.35B | +52% | -4% | 5% | 6.7× | 14.1% | +0.8% |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.36B | -66% | +23% | 7% | n/a | n/a | n/a |
| NewAmsterdam Pharma NAMS | United States | $2.37B | -45% | -26% | -900% | n/a | n/a | n/a |
| Regencell Bioscience RGC | United States | $2.33B | -83% | n/a | n/a | n/a | n/a | n/a |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.38B | +14% | -9% | -6% | 35.9× | 47.0% | +19.3% |
| Acrobiosystems 301080.SZ | China | $2.31B | +65% | +29% | 17% | 55.2× | 41.3% | +27.7% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.39B | +7% | 0% | -73% | 18.2× | n/a | n/a |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.40B | -33% | +153% | -7% | 85.2× | 37.9% | +22.9% |
| Prestige Consumer Healthcare PBH | United States | $2.40B | +7% | +5% | 25% | 10.6× | 2.3% | +2.9% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.25B | -7% | +4% | 10% | n/a | -2.5% | -5.8% |
| Almirall ALM.MC | Spain | $2.46B | -13% | +24% | 8% | 27.1× | 6.1% | +6.5% |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.49B | -24% | -14% | 16% | 27.6× | 3.4% | +4.8% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.20B | +39% | +20% | 12% | 25.0× | 26.7% | +6.5% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.19B | -12% | +18% | n/a | 25.4× | 0.9% | +0.3% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% | -1.5% |
| IDEAYA Biosciences IDYA | United States | $2.56B | -11% | -83% | -1,267% | n/a | n/a | n/a |
| Kangmei Pharmaceutical 600518.SS | China | $2.61B | -21% | -6% | -7% | n/a | n/a | n/a |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 15.4× | -11.0% | +37.6% |
| BioArctic BIOA-B.ST | Sweden | $2.66B | -9% | -46% | 22% | 52.9× | 25.5% | +100.1% |
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 11.9× | 3.2% | +15.7% |
| InnoCare Pharma 688428.SS | China | $2.07B | -7% | +135% | 35% | 85.7× | -10.9% | +344.2% |
Perrigo has 3 bonds outstanding with $1.77B face value. The agencies rate it B+; its bonds trade like BB. Weighted yield 6.75%, a spread of 184 bp over government bonds.